Rothschild Investment Corp IL cut its holdings in shares of Compugen Ltd. (NASDAQ:CGEN) by 3.7% during the second quarter, Holdings Channel.com reports. The firm owned 348,201 shares of the biotechnology company’s stock after selling 13,550 shares during the period. Rothschild Investment Corp IL’s holdings in Compugen were worth $1,337,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also added to or reduced their stakes in the company. Millennium Management LLC bought a new position in shares of Compugen during the fourth quarter valued at approximately $60,000. Virtu Financial LLC bought a new position in shares of Compugen during the first quarter valued at approximately $153,000. Stockman Wealth Management Inc. bought a new position in shares of Compugen during the first quarter valued at approximately $286,000. Defender Capital LLC. boosted its stake in shares of Compugen by 7.2% during the first quarter. Defender Capital LLC. now owns 311,333 shares of the biotechnology company’s stock valued at $1,299,000 after purchasing an additional 20,800 shares in the last quarter. Finally, Nikko Asset Management Americas Inc. boosted its stake in shares of Compugen by 14,153.9% during the first quarter. Nikko Asset Management Americas Inc. now owns 886,590 shares of the biotechnology company’s stock valued at $3,670,000 after purchasing an additional 880,370 shares in the last quarter. Hedge funds and other institutional investors own 27.91% of the company’s stock.

Shares of NASDAQ CGEN traded down $0.13 during midday trading on Monday, reaching $3.28. 3,530 shares of the company’s stock traded hands, compared to its average volume of 92,447. The company has a debt-to-equity ratio of 0.11, a quick ratio of 5.11 and a current ratio of 5.11. The stock’s 50 day moving average is $3.56. Compugen Ltd. has a one year low of $2.00 and a one year high of $4.31. The stock has a market cap of $174.91 million, a P/E ratio of -7.98 and a beta of 2.66.

Compugen (NASDAQ:CGEN) last released its quarterly earnings data on Monday, May 20th. The biotechnology company reported ($0.14) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.17) by $0.03. Equities analysts predict that Compugen Ltd. will post -0.54 EPS for the current fiscal year.

Separately, Zacks Investment Research downgraded shares of Phoenix New Media from a “hold” rating to a “sell” rating in a research note on Tuesday, July 23rd.

Compugen Company Profile

Compugen Ltd., a therapeutic discovery company, engages in the research, development, and commercialization of therapeutic and product candidates in Israel and Europe. The company's therapeutic pipeline consists of immuno-oncology programs against novel drug targets in the areas of unmet medical needs in various cancer types and patient populations.

See Also: Blockchain

Want to see what other hedge funds are holding CGEN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Compugen Ltd. (NASDAQ:CGEN).

Institutional Ownership by Quarter for Compugen (NASDAQ:CGEN)

Receive News & Ratings for Compugen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Compugen and related companies with MarketBeat.com's FREE daily email newsletter.